Lawrence Tim Goodnough
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lawrence Tim Goodnough has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
Kurt Merkel
From the Departments of Medicine and Pathology, Anesthesia, and Orthopedics, Washington University School of Medicine, St. Louis, Missouri; and the Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida
3 shared publicationsTerri G. Monk
From the Departments of Medicine and Pathology, Anesthesia, and Orthopedics, Washington University School of Medicine, St. Louis, Missouri; and the Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida
3 shared publicationsBarry Skikne
From the Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; the Department of Medicine, University of Kansas Medical Center, Kansas City, KS; and the Departments of Laboratory Medicine and Pathology, Children's Hospital, Harvard Medical School, Boston, MA
2 shared publicationsCarlo Brugnara
From the Departments of Medicine and Pathology and Immunology, Washington University School of Medicine, St. Louis, MO; the Department of Medicine, University of Kansas Medical Center, Kansas City, KS; and the Departments of Laboratory Medicine and Pathology, Children's Hospital, Harvard Medical School, Boston, MA
2 shared publicationsGeorge J. Despotis
From the Departments of Medicine and Pathology, Anesthesia, and Orthopedics, Washington University School of Medicine, St. Louis, Missouri; and the Department of Anesthesiology, University of Florida College of Medicine, Gainesville, Florida
2 shared publicationsJeffrey McCullough
From the Departments of Medicine and Pathology, Washington University, St Louis, MO; Departments of Medicine and Pathology, Massachusetts General Hospital, Boston, MA; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis; Puget Sound Blood Center and University of Washington School of Medicine, Seattle; Department of Medicine, Emory University School of Medicine, Atlanta, GA; Blood Center of Southeastern Wisconsin, Milwaukee; and Amgen, Thousand Oaks, CA
2 shared publications
Latest Publications
- 1 January 2015
- Vol. 45 (2) , 140-7
Infusion pump-mediated mechanical hemolysis in pediatric patients.
Hemoglobinuria was observed after packed red blood cell transfusion in a series of patients at our pediatric treatment center. Laboratory testing was suggestive of intravascular hemolysis with no support for an immunohematologic process. We investigated these adverse events to define a quality improvement plan and to prevent future hemolytic adverse events. Multiple factors were investigated, and the only change identified was the implementation of a new infusion pump (Pump A) that replaced a previous model (Pump B). In vitro pump analyses, a retrospective review of urinalyses, and prospective urinalysis and nursing surveillances were also performed. In in vitro analysis of the pumps, irradiated units with higher hematocrit at a low flow rate through Pump A had a greater than thirty-fold increase in free hemoglobin from baseline compared to minimal free hemoglobin changes seen with Pump B. Irradiated units with a lower hematocrit had a minimal change in free hemoglobin from baseline with both Pumps A and B at either low or high flow rate. Subsequently, only units with lower hematocrits were issued for transfusion of pediatric patients, and Pump A was replaced by Pump B in the outpatient unit. Retrospective and prospective surveillances found no additional unexplained cases of gross hemoglobinuria associated with transfusion. The investigation determined that infusion of higher hematocrit units using a specific commercial pump was associated with mechanical hemolysis. The change to units with lower hematocrit through an alternative pump has been an effective corrective action to date.
- 1 January 2015
- Vol. 45 (2) , 140-7
Infusion pump-mediated mechanical hemolysis in pediatric patients.
Hemoglobinuria was observed after packed red blood cell transfusion in a series of patients at our pediatric treatment center. Laboratory testing was suggestive of intravascular hemolysis with no support for an immunohematologic process. We investigated these adverse events to define a quality improvement plan and to prevent future hemolytic adverse events. Multiple factors were investigated, and the only change identified was the implementation of a new infusion pump (Pump A) that replaced a previous model (Pump B). In vitro pump analyses, a retrospective review of urinalyses, and prospective urinalysis and nursing surveillances were also performed. In in vitro analysis of the pumps, irradiated units with higher hematocrit at a low flow rate through Pump A had a greater than thirty-fold increase in free hemoglobin from baseline compared to minimal free hemoglobin changes seen with Pump B. Irradiated units with a lower hematocrit had a minimal change in free hemoglobin from baseline with both Pumps A and B at either low or high flow rate. Subsequently, only units with lower hematocrits were issued for transfusion of pediatric patients, and Pump A was replaced by Pump B in the outpatient unit. Retrospective and prospective surveillances found no additional unexplained cases of gross hemoglobinuria associated with transfusion. The investigation determined that infusion of higher hematocrit units using a specific commercial pump was associated with mechanical hemolysis. The change to units with lower hematocrit through an alternative pump has been an effective corrective action to date.
- 1 January 2008
- Published by Springer Nature
- p. 679-701
Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy
- 1 January 2008
- Published by Springer Nature
- p. 679-701
Erythropoiesis, iron metabolism and iron supplementation during erythropoietin therapy
- 1 January 2008
- Published by Springer Nature
- p. 663-677
rhEPO in surgical oncology
- Open Access
- 1 January 2004
- Published by Springer Nature in Critical Care
- Vol. 8 (Suppl 2) , S49-52
Autologous blood donation
Although preoperative autologous blood donation is employed in elective surgery, this is declining because of the increasingly safe allogeneic blood supply. However, it continues to be used because of the public's perception of allogeneic blood risks and increasing blood shortages. Patients may donate a unit of blood (450 ± 45 ml) as often as twice weekly, up to 72 hours before surgery. Preoperative autologous blood is most beneficial in procedures that cause significant blood loss. It has been determined that preoperative autologous blood donation is poorly cost-effective; the use of this procedure must be based on evidence that it is safe and of value for the patient.
- 1 January 2004
- Published by Springer Nature in Critical Care
- Vol. 8 (Suppl 2) , S49-52
Open AccessAutologous blood donation
Although preoperative autologous blood donation is employed in elective surgery, this is declining because of the increasingly safe allogeneic blood supply. However, it continues to be used because of the public's perception of allogeneic blood risks and increasing blood shortages. Patients may donate a unit of blood (450 ± 45 ml) as often as twice weekly, up to 72 hours before surgery. Preoperative autologous blood is most beneficial in procedures that cause significant blood loss. It has been determined that preoperative autologous blood donation is poorly cost-effective; the use of this procedure must be based on evidence that it is safe and of value for the patient.
- 16 July 2003
- Published by Georg Thieme Verlag KG in Zentralblatt fur Chirurgie
- Vol. 128 (6) , 462-467
Autologe Blutgewinnung - akute normovolämische Hämodilution vs. präoperative Eigenblutspende
Die autologe Blutspende ist in der Evolution begriffen. Anfang der 80er-Jahre nahm das Interesse an der präoperativen autologen Blutspende rapide zu, als erkannt wurde, dass mit Blut das HIV-Virus übertragen werden kann. Seit 1992 haben jedoch die Aktivitäten auf diesem Gebiet deutlich abgenommen, bei gleichzeitiger erhöhter Sicherheit der Bluttransfusion. Die Gründe für diese Abnahme der Aktivitäten sind nicht ganz klar; zum einen wird von den Patienten aufgrund der restriktiveren Transfusionsbestimmungen die Bluttransfusion als sicherer angesehen, hinzu kommen aber auch die hohen Kosten der präoperativen autologen Blutspende, die darauf beruhen, dass 50 % der gewonnenen Transfusionseinheiten verworfen werden. Eine alternative Strategie besteht in der akuten normovolämischen Hämodilution, die bei geringeren Kosten den Vorzug hat, die Verlustraten der gewonnenen Blutkonserven gering zu halten. Ein weiterer Vorteil der akuten normovolämischen Hämodilution ist die Tatsache, dass die Blutspende immer am Patientenbett durchgeführt wird. Damit lassen sich Fehler bei der Administration der Blutkonserven vermeiden, die zu einer transfusionsbedingten Hämolyse führen können, wie das mit Blut, das präoperativ gewonnen und in der Blutbank gelagert wird, durchaus vorkommt. Das Interesse an der autologen Blutspende könnte auf diese Weise wieder neu entfacht werden, in Anbetracht der beschränkten Verfügbarkeit von Fremdblut, unabhängig von Risiko- und Kostenaspekten. Autologous blood procurement remains in evolution. Interest in preoperative autologous blood donation (PAD) increased substantially in the 1980‘s due to the recognition that HIV was transmissible by blood. Concomitant with increased blood safety, however, PAD activity has declined approximately 40 % since 1992. Reasons for this decline are unclear; patients may feel more comfortable with issues regarding blood safety, but associated costs and discard rates of up to 50 % of blood units are other important factors. An alternate strategy is acute normovolemic hemodilution (ANH), which has the advantages of lower costs along with no wastage of blood units. A further advantage is that since ANH units never leave the patient’s bedside, there is no possibility of an administrative error that could lead to ABO-related hemolysis (as could occur with PAD units stored in the blood bank). Concerns regarding the adequacy of national blood inventories may restimulate interest in autologous blood procurement, independent of issues regarding blood risks or costs.
- 16 July 2003
- Published by Georg Thieme Verlag KG in Zentralblatt fur Chirurgie
- Vol. 128 (6) , 462-467
Autologe Blutgewinnung - akute normovolämische Hämodilution vs. präoperative Eigenblutspende
Die autologe Blutspende ist in der Evolution begriffen. Anfang der 80er-Jahre nahm das Interesse an der präoperativen autologen Blutspende rapide zu, als erkannt wurde, dass mit Blut das HIV-Virus übertragen werden kann. Seit 1992 haben jedoch die Aktivitäten auf diesem Gebiet deutlich abgenommen, bei gleichzeitiger erhöhter Sicherheit der Bluttransfusion. Die Gründe für diese Abnahme der Aktivitäten sind nicht ganz klar; zum einen wird von den Patienten aufgrund der restriktiveren Transfusionsbestimmungen die Bluttransfusion als sicherer angesehen, hinzu kommen aber auch die hohen Kosten der präoperativen autologen Blutspende, die darauf beruhen, dass 50 % der gewonnenen Transfusionseinheiten verworfen werden. Eine alternative Strategie besteht in der akuten normovolämischen Hämodilution, die bei geringeren Kosten den Vorzug hat, die Verlustraten der gewonnenen Blutkonserven gering zu halten. Ein weiterer Vorteil der akuten normovolämischen Hämodilution ist die Tatsache, dass die Blutspende immer am Patientenbett durchgeführt wird. Damit lassen sich Fehler bei der Administration der Blutkonserven vermeiden, die zu einer transfusionsbedingten Hämolyse führen können, wie das mit Blut, das präoperativ gewonnen und in der Blutbank gelagert wird, durchaus vorkommt. Das Interesse an der autologen Blutspende könnte auf diese Weise wieder neu entfacht werden, in Anbetracht der beschränkten Verfügbarkeit von Fremdblut, unabhängig von Risiko- und Kostenaspekten. Autologous blood procurement remains in evolution. Interest in preoperative autologous blood donation (PAD) increased substantially in the 1980‘s due to the recognition that HIV was transmissible by blood. Concomitant with increased blood safety, however, PAD activity has declined approximately 40 % since 1992. Reasons for this decline are unclear; patients may feel more comfortable with issues regarding blood safety, but associated costs and discard rates of up to 50 % of blood units are other important factors. An alternate strategy is acute normovolemic hemodilution (ANH), which has the advantages of lower costs along with no wastage of blood units. A further advantage is that since ANH units never leave the patient’s bedside, there is no possibility of an administrative error that could lead to ABO-related hemolysis (as could occur with PAD units stored in the blood bank). Concerns regarding the adequacy of national blood inventories may restimulate interest in autologous blood procurement, independent of issues regarding blood risks or costs.
- 1 January 2003
- Published by Elsevier in The Lancet
- Vol. 361 (9352) , 161-169
Transfusion medicine: looking to the future
- 1 January 2003
- Published by Elsevier in The Lancet
- Vol. 361 (9352) , 161-169
Transfusion medicine: looking to the future
- 1 November 2002
- Vol. 16 (11) , 1558
Issues in the management of cancer-related thrombocytopenia.
Thrombocytopenia remains a significant clinical problem for patients with cancer. Management approaches include watchful waiting, platelet transfusions, and the use of pharmacologic agents. Although platelet transfusion remains the gold standard for prophylaxis and treatment of thrombocytopenia, this approach is associated with transfusion-transmitted disease, infection, and platelet refractoriness. Because of these complications and the expense of platelet therapy, recent studies have examined the clinical evidence supporting the widely used platelet transfusion trigger of 20,000 cells/microL and found that values of 5,000 to 10,000 cells/microL are safe for selected patients. Several investigational agents offer promise for treatment of thrombocytopenia in patients undergoing myelosuppressive and myeloablative therapy. These agents include recombinant human interleukin-11, recombinant human thrombopoietin, and c-Mpl ligand mimetics.
- 1 November 2002
- Vol. 16 (11) , 1558
Issues in the management of cancer-related thrombocytopenia.
Thrombocytopenia remains a significant clinical problem for patients with cancer. Management approaches include watchful waiting, platelet transfusions, and the use of pharmacologic agents. Although platelet transfusion remains the gold standard for prophylaxis and treatment of thrombocytopenia, this approach is associated with transfusion-transmitted disease, infection, and platelet refractoriness. Because of these complications and the expense of platelet therapy, recent studies have examined the clinical evidence supporting the widely used platelet transfusion trigger of 20,000 cells/microL and found that values of 5,000 to 10,000 cells/microL are safe for selected patients. Several investigational agents offer promise for treatment of thrombocytopenia in patients undergoing myelosuppressive and myeloablative therapy. These agents include recombinant human interleukin-11, recombinant human thrombopoietin, and c-Mpl ligand mimetics.
- 1 November 2002
- Vol. 1 (2) , 119-23
Red cell growth factors in patients with chronic anemias.
Erythropoetin therapy has been approved for treatment of medical anemia since 1989. The adoption of this strategy has been rapid in some settings (e.g., renal failure patients) and progressive in others (e.g., cancer patients). Although the risks of blood transfusion have declined substantially, risks associated with (untreated) anemia have undergone new scrutiny. Options such as novel erythropoiesis-stimulating protein bring new alternatives to blood transfusion. Erythropoietin therapy is undergoing renewed scrutiny in the management of anemia, not only because of traditional concerns regarding blood risks but because emerging evidence suggests that improved patient outcomes result from management of anemia.
- 1 November 2002
- Vol. 1 (2) , 119-23
Red cell growth factors in patients with chronic anemias.
Erythropoetin therapy has been approved for treatment of medical anemia since 1989. The adoption of this strategy has been rapid in some settings (e.g., renal failure patients) and progressive in others (e.g., cancer patients). Although the risks of blood transfusion have declined substantially, risks associated with (untreated) anemia have undergone new scrutiny. Options such as novel erythropoiesis-stimulating protein bring new alternatives to blood transfusion. Erythropoietin therapy is undergoing renewed scrutiny in the management of anemia, not only because of traditional concerns regarding blood risks but because emerging evidence suggests that improved patient outcomes result from management of anemia.
- 1 August 2002
- Published by Wiley in Vox Sanguinis
- Vol. 83 (s1) , 211-215
Acute Normovolemic Hemodilution
- 1 August 2002
- Published by Wiley in Vox Sanguinis
- Vol. 83 (s1) , 211-215
Acute Normovolemic Hemodilution